Compound having anticancer effect

A novel compound targeting nutrient-starved cancer cells by inhibiting Akt/mTOR activation and autophagy provides an effective treatment for pancreatic cancer, addressing the limitations of current chemotherapy by selectively killing cancer cells and inhibiting tumor growth.

JP2024161628AInactive Publication Date: 2024-11-20UNIVERSITY OF TOYAMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021124439
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-07-29
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current chemotherapy treatments for pancreatic cancer are limited in effectiveness, and there is a need for improved chemotherapeutic agents that can target nutrient-starved cancer cells, which are resistant to nutrient deprivation and hypoxic conditions.

Method used

Development of a novel compound represented by formula (I) that acts as an Akt/mTOR activation inhibitor and autophagy activation inhibitor, selectively killing cancer cells under nutrient-starved conditions while being non-toxic in nutrient-rich states, and can be used alone or in combination with existing anticancer drugs.

Benefits of technology

The compound effectively targets and kills cancer cells, including cancer stem cells, by inhibiting Akt/mTOR activation and autophagy, thereby inhibiting tumor growth and colony formation, and demonstrates cytotoxicity specifically in nutrient-starved environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161628000014
    Figure 2024161628000014
  • Figure 2024161628000015
    Figure 2024161628000015
  • Figure 2024161628000016
    Figure 2024161628000016
Patent Text Reader

Abstract

To provide novel compounds and pharmaceutical compositions with anti-cancer effects.SOLUTION: The present invention provides a following compound (I), such as (trans-4'-methyl-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(4-methoxy-2,6-bis(methoxymethoxy)phenyl)methanone.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel compounds of formula (I) or their stereoisomers, tautomers, or pharma- ceutically acceptable salts, which have anticancer activity. The present invention also relates to pharmaceutical compositions containing such compounds, and their uses. [Background technology]

[0002] Pancreatic cancer has the lowest 5-year survival rate among all solid cancers, and has an extremely poor prognosis. Although surgery is the most effective treatment, chemotherapy plays a major role preoperatively and postoperatively. Previously, gemcitabine was used as the first-line chemotherapy drug for pancreatic cancer, but in recent years, multidrug combinations have become mainstream. FOLFIRINOX therapy, which combines fluorouracil, oxaliplatin, irinotecan, etc., and TS-1, which is only available in Japan, are also used as an oral drug. In addition, drug delivery systems aimed at reducing side effects, such as nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) and Onivyde (irinotecan-liposome injection), are also being used as liposomal preparations.

[0003] As mentioned above, various chemotherapy methods have been proposed for pancreatic cancer. However, currently, there are very few effective chemotherapeutic agents for pancreatic cancer treatment, and their effects are limited. In searching for new anticancer drugs, a new method has been proposed in the field of anticancer drug discovery, called the "antiausterity strategy," which focuses on candidate drugs that suppress the survival ability of cancer cells under nutrient-starved conditions.

[0004] Cancer cells generally have the property of being able to grow in a disorderly and rapid manner, but the tumor vasculature formed is fragile and irregular, which means that they are exposed to an environment lacking in nutrients and oxygen. However, when cancer cells are placed in extreme conditions such as malnutrition and hypoxia, they exhibit a unique resistance mechanism that allows them to survive by changing their energy metabolism. In particular, human pancreatic cancer cells such as PANC-1 have acquired such resistance, and are able to survive for long periods of time even in harsh environments such as malnutrition and hypoxia.

[0005] Compounds that relieve such resistance of cancer cells to nutrient starvation are the subject of research into new anticancer drugs, and examples of such compounds include isopanduratin A1 and nicolaidecin C (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Nhan Trung Nguyen, et.al., Journal of Natural Produces 2017, 80, 141-148 Summary of the Invention [Problem to be solved by the invention]

[0007] Most pancreatic cancer patients develop metastasis quickly and die within a short period of time. As mentioned above, various chemotherapy methods have been proposed for pancreatic cancer, but there are currently very few effective chemotherapeutic agents for pancreatic cancer treatment, and their effectiveness is limited. Therefore, further improvements in the treatment of pancreatic cancer are required. [Means for solving the problem]

[0008] The present inventors found that Nicolaidesin C exerts its anticancer effect as an Akt / mTOR activation inhibitor and also has the effect of promoting cancer cell death as an autophagy activation inhibitor, and focused on Nicolaidesin C. The present inventors attempted to explore the activity of newly synthesized Nicolaidesin C derivatives that show no toxicity in nutrient-rich conditions and show toxicity to cancer cells only in nutrient-starved conditions, which is completely different from the mechanism of action of existing anticancer drugs. As a result, the inventors discovered compounds with novel anticancer effects that have a completely different mechanism of action from existing anticancer drugs for pancreatic cancer, and confirmed that these compounds have almost no serious side effects specific to anticancer drugs. Furthermore, the inventors confirmed that the compounds of the present invention alone and in combination with existing anticancer drugs provide revolutionary drugs that exhibit anticancer effects, and thus completed the present invention.

[0009] Therefore, the present invention includes the following aspects. <Compound> [1] Formula (I): [ka] [In the formula, R1~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, any of which (excluding hydrogen, hydroxy and halogen) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN. However, R1 is methoxy, R2, R5, R6, R7, R8, R9 and R 10 is hydrogen, and R3 and R4 are hydroxy. or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

[0010] [2] Formula (I): [ka] [In the formula, R1 to R5 each independently represent hydrogen, hydroxy, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, all of which (except hydrogen and hydroxy) are -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10) heteroaryl, any of which (excluding hydrogen, hydroxy and halogen) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted with one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN. The compound according to [1], or a stereoisomer, a tautomer, or a pharma- ceutically acceptable salt thereof, wherein:

[0011] [3] In formula (I), R1 to R5 each independently represent hydrogen, hydroxy, or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof according to [1] or [2]. [4] In formula (I), R1 is hydrogen or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, according to any one of [1] to [3]. [5] A compound according to any one of [1] to [4], wherein in formula (I), R2 is hydrogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof. [6] In formula (I), R3 is hydroxy or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof according to any one of [1] to [5]. [7] In formula (I), R4 is hydrogen, hydroxy or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof according to any one of [1] to [6].

[0012] [8] A compound according to any one of [1] to [7], wherein in formula (I), R5 is hydrogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof. [9] In formula (I), R to R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof according to any one of [1] to [8].

[10] [9] The compound according to the formula (I), wherein R6 is hydrogen or halogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

[11] The compound according to [9] or

[10] , wherein in formula (I), R7 is hydrogen or halogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

[0013]

[12] In formula (I), R8 is hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl or -O-(C 1-6 ) alkyl, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, according to any one of [9] to

[11] .

[13] A compound according to any one of [9] to

[11] , or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein, in formula (I), one or more of R6, R7, and R8 are halogen.

[14] A compound according to any one of [9] to

[13] , wherein in formula (I), R9 is hydrogen or halogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

[15] In formula (I), R 10is hydrogen or halogen, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof according to any one of [9] to

[14] .

[0014] <Pharmaceutical Composition>

[16] A pharmaceutical composition comprising a compound represented by formula (I) according to any one of [1] to

[15] , or a stereoisomer, tautomer, or pharma- ceutical acceptable salt thereof.

[17] The pharmaceutical composition described in

[16] , which selectively kills tumor cells in a nutrient-starved state.

[18] The pharmaceutical composition of

[16] or

[17] , which targets the tumor microenvironment.

[19] A pharmaceutical composition described in any of

[16] to

[18] for treating or preventing pancreatic cancer.

[20] A pharmaceutical composition based on a combination of a compound of formula (I) as defined in any one of [1] to

[15] , or a stereoisomer, tautomer, or pharma- ceutical acceptable salt thereof, and at least one other anticancer agent. [twenty one]

[20] A pharmaceutical composition based on the combination described in, wherein the other anticancer drug is selected from the group consisting of gemcitabine, albumin-bound paclitaxel, TS-1, gemcitabine and albumin-bound paclitaxel, gemcitabine and TS-1, forfirinox therapy, modified forfirinox therapy, and liposomal irinotecan and 5FU / LV.

[0015] <Use> [twenty two] Use of a compound according to any one of [1] to

[15] , or a stereoisomer, tautomer, or pharma- ceutical acceptable salt thereof, as an anticancer agent that selectively kills nutrient-starved tumor cells. [twenty three] Use of a compound according to any one of [1] to

[15] , or a stereoisomer, tautomer, or pharma- ceutical acceptable salt thereof, as an anticancer agent that targets the tumor microenvironment. Effect of the Invention

[0016] The present invention is an approach that focuses particularly on cytotoxicity in the cancer microenvironment, i.e., in a state of nutrient starvation, and proposes a groundbreaking pharmaceutical compound that is highly likely to be effective against cancer stem cells and can effectively kill cancer cells through multiple mechanisms of action. [Brief description of the drawings]

[0017] [Figure 1] Figure 1 shows the morphological changes of untreated cells (i.e., control) in nutrient-starved medium (NDM), PANC-1 (A) and MIA PaCa-2 (B) cells treated with nicolaidecin C (NICO-C). EB: ethidium bromide, AO: acridine orange, phase contrast represents the result of converting the phase difference of the light beam into contrast, and overlay shows the overlay of green fluorescence + red fluorescence + black and white images of each column. [Diagram 2] Figure 2 shows the effect of nicolaidecin C (NICO-C) on colony formation by PANC-1 cells. Figure 2A is a photograph showing PANC-1 cell colonies treated with different concentrations of nicolaidecin C. Figure 2B is a graph showing the average area occupied by PANC-1 cell colonies (three replicates). **** p < 0.0001, * p < 0.05 compared to the untreated control group.

[0018] [Diagram 3] Figure 3 shows the results of electrophoresis showing the effect of nicolaidecin C (NICO-C) on key proteins involved in the Akt / mTOR and autophagy signaling pathways in PANC-1 (A) and MIA PaCa-2 (B) cell lines. [Figure 4]Figure 4 shows the results of electrophoresis showing the inhibitory effect of nicolaidecin C on autophagy markers LC3-I and LC3-II. The effect of nicolaidecin C (20 μM) is compared with that of chloroquine (CQ, 25 μM) and 3-methyladenine (3-MA, 5 mM). [Diagram 5] 5 is a result of electrophoresis showing the inhibitory effect of nicolaidecin C on the phosphorylation of Akt induced by IGF-1. The effect of nicolaidecin C (20 μM) is compared with the effect of the Akt inhibitor [(2R)-2-methoxy-3-octadecoxypropyl][2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl]carbonate (10 μM). [Figure 6] Figure 6 is a graph showing the effect of nicolaidecin C on the growth of MIA PaCa-2 tumors in nude mice. (A) Body weight, (B) mean tumor volume and SEM (n = 8 / group, low dose = 50 μg / d; high dose = 250 μg / d, intraperitoneal administration, 5 days per week), and (C) wet weight of tumors in mice on the last day of the experiment. Statistical significance: two-way ANOVA and Tukys test, ** P < 0.01, **** P < 0.0001. [Figure 7A] FIG. 7A is a graph showing the selective cytotoxic activity of nicolaidecin C (NICO-C) against the PANC-1 human pancreatic cancer cell line in nutrient-depleted medium (NDM) and Dulbecco's modified Eagle's medium (DMEM). [Figure 7B] FIG. 7B is a graph showing the selective cytotoxic activity of compounds of the present invention (compounds NICO-1 to NICO-12) against the PANC-1 human pancreatic cancer cell line in nutrient-depleted medium (NDM) and Dulbecco's modified Eagle's medium (DMEM). [Figure 7C] FIG. 7C is a graph showing the selective cytotoxic activity of compounds of the present invention (compounds NICO-13 to NICO-24) against the PANC-1 human pancreatic cancer cell line in nutrient-depleted medium (NDM) and Dulbecco's modified Eagle's medium (DMEM). [Figure 7D]FIG. 7D is a graph showing the selective cytotoxic activity of compounds of the present invention (compounds NICO-25 to NICO-31) and nicolaidecin C (NICO-C) against the PANC-1 human pancreatic cancer cell line in nutrient-depleted medium (NDM) and Dulbecco's modified Eagle's medium (DMEM). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Unless otherwise stated, the following terms used in the specification and claims have the meanings given below.

[0020] As used herein, the term "(C 1-6 (C)Alkyl" means a branched or straight chain aliphatic hydrocarbon containing 1 to 6 carbon atoms. 1-6 Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. 1-6 ) Alkyl is methyl, ethyl or isopropyl.

[0021] As used herein, the term "hydroxy" refers to an --OH group, which may also be referred to as a hydroxyl group or a hydroxyl group.

[0022] As used herein, the term "halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. Preferably, the halogen is fluorine, chlorine or bromine.

[0023] As used herein, the term "halo(C 1-6 "C )alkyl" refers to the alkyl radicals defined above in which one or more hydrogen atoms of the same or different carbon atoms are replaced by the same or different halogens. 1-6 ) alkyl. Halo(C 1-6 ) Examples of alkyl include, but are not limited to, fluoromethyl, chloromethyl, fluoroethyl, difluoromethyl, dichloromethyl, trifluoromethyl, difluoroethyl, and the like.

[0024] As used herein, the term "-O-(C1-6)alkyl" refers to -O-(C1-6)alkyl, as defined above. 1-6 )alkyl) monovalent group, which is also referred to as alkoxy or alkyloxy. Examples of "-O-(C1-6)alkyl" include -O-C1-6alkyl (i.e., C1-6alkoxy), -O-C1-4alkyl (i.e., C1-4alkoxy), and the like. Further specific examples include, but are not limited to, methoxy (CHO-), ethoxy (CHCHO-), n-propoxy (CH(CH)O-), isopropoxy ((CHCHO-), n-butoxy (CH(CH)O-), isobutoxy ((CH)CHCHO-), tert-butoxy ((CHCO-), sec-butoxy (CHCHCH(CH)O-), n-pentyloxy (CH(CH)O-), isopentyloxy ((CH)CHCHCHO-), neopentyloxy ((CHCHO-), tert-pentyloxy (CHCHC(CH)O-), 1,2-dimethylpropoxy (CHCH(CH)CH(CH)O-), and the like.

[0025] As used herein, the term "-S-(C1-6)alkyl" refers to -S-(as defined above (C 1-6 )alkyl) monovalent group, sometimes referred to as alkylthio. Examples of "-S-(C1-6)alkyl" include "C1-4 alkylthio" and "C1-3 alkylthio". Specific examples of "-S-(C1-6)alkyl" include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, isopropylthio, isobutylthio, tert-butylthio, sec-butylthio, isopentylthio, neopentylthio, tert-pentylthio, 1,2-dimethylpropylthio, and the like.

[0026] As used herein, the term "(C 3-6 "Cycloalkyl" means a saturated monocyclic hydrocarbon ring containing from 3 to 6 carbon atoms. 3-6) Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0027] As used herein, the term "(C 6-10 "Aryl" means an aromatic hydrocarbon ring containing from 6 to 10 carbon atoms. 6-10 ) Examples of aryl groups include, but are not limited to, phenyl or naphthyl, and the like.

[0028] As used herein, the term "(C 5-10 "Heteroaryl" means an aromatic monocyclic or bicyclic heterocyclic ring system containing 5 to 10 atoms. 5-10 ) Examples of heteroaryl groups include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiazolyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzodioxolyl, benzofuranyl, benzofurazanyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzotriazolyl, benzothiophenyl, benzoxazepinyl, benzo Examples of such radicals include, but are not limited to, oxazinonyl, benzoxazolyl, benzoxazolyl, imidazopyridinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyrazinyl, imidazopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, pyrazolotriazinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, and N-oxides thereof.

[0029] As used herein, the term "stereoisomer" refers to an isomer of the compound of formula (I) that differs in the spatial arrangement of its atoms. The compounds disclosed herein can exist as single stereoisomers, racemates, and / or mixtures of enantiomers and / or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are included within the scope of the present invention.

[0030] As used herein, the term "pharmaceutical acceptable salts" refers to salts of active compounds, i.e., compounds of formula (I), which are prepared by reaction with a suitable acid or acid derivative, depending on the particular substituents found in the compounds described herein.

[0031] (Mode of Implementation) The present invention includes, without limitation, all compounds described as compounds of formula (I), but preferred embodiments of the present invention will be described as embodiments herein below.

[0032] In one embodiment, the present invention provides a compound of formula (I): Formula (I): [ka] [In the formula, R1 to R5 each independently represent hydrogen, hydroxy, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, all of which (except hydrogen and hydroxy) are -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, any of which (excluding hydrogen, hydroxy and halogen) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted with one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN. or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof; Regarding.

[0033] In another embodiment, the present invention provides a compound represented by formula (I): 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, or halo(C 1-6 ) alkyl, all of which (except hydrogen and hydroxy) are —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, or halo(C 1-6 ) alkyl, all of which (excluding hydrogen, hydroxy and halogen) are —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; or a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

[0034] In another embodiment, the present invention provides a compound represented by formula (I): 6-10 )aryl or -(C 5-10 ) heteroaryl, each of which is -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, each of which is -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; or a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

[0035] In another embodiment, the present invention provides a compound represented by formula (I): 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, or halo(C 1-6 ) alkyl, all of which (except hydrogen and hydroxy) are —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, each of which is -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; or a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

[0036] In another embodiment, the present invention provides a compound represented by formula (I): 6-10)aryl or -(C 5-10 ) heteroaryl, each of which is -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) may be substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; R6~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, or halo(C 1-6 ) alkyl, all of which (excluding hydrogen, hydroxy and halogen) are —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) optionally substituted by one or more substituents selected from alkyl, -N(CH3)2, halogen, hydroxy, -NH2 and -CN; or a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

[0037] In one embodiment, the present invention provides a compound of formula (I): [ka] [In the formula, R1 is hydrogen, -O-(C 1-6 ) alkyl; R2 is hydrogen; R3 is hydroxy, -O-(C 1-6 ) alkyl; R4 is hydrogen, hydroxy, -O-(C 1-6 ) alkyl; R5 is hydrogen; R6 is hydrogen or halogen; R7 is hydrogen or halogen; R8 is hydrogen, halogen, -O-(C 1-6 ) alkyl; R9 is hydrogen or halogen; R 10 are hydrogen and halogens] or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof; Regarding.

[0038] (Utility of the Compound of the Present Invention) Hereinafter, the usefulness of the compound of the present invention will be explained in comparison with nicolaidecin C (Non-Patent Document 1), which is known as a compound that relieves resistance to nutrient starvation. Nicolaidecine C has the formula: [ka] (Gu, J.-Q., et al., Nat. Prod. 2002, 65, 1616-1620).

[0039] Selective cytotoxic activity The present inventors confirmed the effect on the PANC-1 human pancreatic cancer cell line in nutrient-starved medium (NDM) and Dulbecco's modified Eagle medium (DMEM), and demonstrated that, like nicolaidecin C (Non-Patent Document 1) (Figure 1A), the compound of the present invention, the nicolaidecin C derivative, exhibits selective cytotoxic activity (Figures 1B, C and D). In other words, it was found that the compound of the present invention, as an anticancer substance targeting the tumor microenvironment, selectively exhibits cytotoxicity against tumor cells under nutrient-starved conditions.

[0040] In tumor masses, many non-tumor cells such as fibroblasts, immune cells, and vascular cells exist, supporting the growth of tumors. These cells and the environment are collectively called the "tumor microenvironment." The characteristic of the tumor microenvironment is that it is specifically hypoxic and low-nutrient environment, and many immature tumor blood vessels are formed due to oxygen deficiency and sugar deficiency signals, resulting in circulatory insufficiency. In addition, in the tumor microenvironment, increased expression of cancer stem cells capable of supplying cancer cells and reconstructing tumor tissue has been observed, and such cancer stem cells are said to be highly malignant and have high metastatic potential. Since the compound of the present invention targets such a tumor microenvironment, it is expected to have an anti-cancer effect against cancer stem cells.

[0041] The selective cytotoxic activity means an activity that does not show toxicity in a nutrient-rich state and shows cytotoxicity only under nutrient-starved conditions. Since the compound of the present invention has such selective cytotoxicity, it is expected that it does not show cytotoxicity to normal cells and shows cytotoxicity specifically to cancer stem cells.

[0042] Akt / mTOR activation inhibitor The compound of the present invention, nicolaidecin C derivative, inhibits Akt activation induced by IGF-1, and is therefore expected to be a new candidate compound for cancer treatment. Akt is a serine / threonine kinase that is activated in the majority of human tumors and controls tumor cell functions such as cell survival, proliferation, metabolism, angiogenesis, migration, and invasion. Akt is activated during nutrient starvation and confers resistance to nutrient starvation. Therefore, targeting the Akt signaling pathway is one of the major therapeutic strategies in cancer treatment. Figure 4 shows the effect of nicolaidecin C on Akt / mTOR activation in human pancreatic cancer cells (PANC-1 and MIA-PaCa 2). The compound of the present invention inhibits Akt / mTOR activation, just like nicolaidecin C.

[0043] Autophagy activation inhibitors The compound of the present invention, nicolaidecine C derivative, as an inhibitor of autophagy activation, is a therapeutic drug for cancer treatment. Autophagy is activated by various factors, such as the depletion of nutrients in the tumor microenvironment due to the active growth of cancer cells. Activation of autophagy allows cancer cells to recycle cellular debris in the tumor microenvironment to ensure energy production and promote cell proliferation. Therefore, autophagy can confer resistance to nutrient starvation in the tumor microenvironment. The present invention has revealed that nicolaidecine C derivative effectively inhibits autophagy markers (LC3-I and LC3-II) and promotes cancer cell death. Autophagy inhibitors can be classified as early or late inhibitors. Early stage inhibitors, such as 3-methyladenine (3-MA), interfere with membrane recruitment and inhibit autophagosome formation. Late stage inhibitors, such as chloroquine (CQ), prevent lysosomal acidification and inhibit autophagosome degradation. It was found that treatment of PANC-1 cells with CQ increased the accumulation of LC3-II in nutrient-deprived medium (NDM). On the other hand, 3-MA suppressed the expression of LC3-II. In the present invention, it was demonstrated that treatment with nicolaidecin C suppressed the expression of both autophagy markers LC3-I and LC3-II at an early stage (Figure 5). The compound of the present invention, like nicolaidecin C, inhibits the activation of autophagy.

[0044] Furthermore, the present invention has demonstrated the effect of nicolaidecin C on cancer colony formation, and has also demonstrated from another aspect that nicolaidecin C is useful for cancer treatment (Figure 3). During cancer invasion and metastasis, the invading cancer cells adapt to the microenvironment of the foreign tissue to form small colonies of cancer cells (micrometastasis), which then grow into large tumors. This phenomenon is called "colony formation." Many patients with pancreatic tumors develop liver metastasis soon after diagnosis. Pancreatic cancer cells tend to migrate to organs that are well nourished and form colonies. The present invention has shown that nicolaidecin C effectively inhibits colony formation of PANC-1 cancer cells in a concentration-dependent manner. The compounds of the present invention inhibit colony formation of cancer cells, similar to nicolaidecin C.

[0045] Nicolaidecin C induces apoptosis accompanied by morphological changes that kill cancer cells (Figure 2), and is therefore expected to be useful in the treatment of cancer. The compound of the present invention, like Nicolaidecin C, is expected to induce apoptosis and be useful in the treatment of cancer.

[0046] The present invention demonstrates that nicolaidecin C inhibits tumor growth in MIA PaCa-2 cancer cell xenograft model mice in a concentration-dependent manner (Figure 7), providing a therapeutic drug that is useful for cancer treatment. The compound of the present invention inhibits tumor growth in cancer cell xenograft model mice, similar to nicolaidecin C.

[0047] Preparation method In another aspect, the present invention relates to methods for preparing the compounds of formula (I) described herein.

[0048] Scheme 1 illustrates a general method for the preparation of compounds of formula (I), where R1-R10 are as defined above. [ka]

[0049] Step 1: General synthesis of chalcone compounds Under an Ar or nitrogen atmosphere, acetophenone compound 1 is added to a polar solvent such as an alcohol solvent, for example, methanol, ethanol, or a mixed solution of these solvents and water, and the corresponding benzaldehyde compound 2 and barium hydroxide octahydrate are added successively at room temperature, and the reaction is allowed to proceed at about 50 to about 80° C., specifically at 60° C., for about a whole day.

[0050] After removing the solvent such as methanol using a rotary evaporator or the like, the mixture is extracted with a polar solvent such as dichloromethane, benzene, toluene, preferably toluene, etc. The organic layers are combined and dried over anhydrous sodium sulfate, after which the solvent is removed using a rotary evaporator or the like, and the resulting residue is purified, for example, by silica gel column chromatography, to obtain the desired chalcone compound.

[0051] Step 2: Preparation of Compounds of Formula (I) Under an Ar or nitrogen atmosphere, myrcene is added to a polar solvent solution of a chalcone compound, specifically a toluene or benzene solution, at room temperature, and the mixture is stirred in a sealed tube, for example, at 160° C. for 7 days. The solvent is removed using a rotary evaporator or the like, and the resulting residue is purified, for example, by silica gel column chromatography, to obtain the desired compound and a mixture of its positional isomers.

[0052] Next, p-toluenesulfonic acid monohydrate (133 mg, 0.07 mmol) is added to the resulting mixture, for example, in a mixed solution of methanol and dichloromethane, and the mixture is stirred for 16 hours at 40° C. After the reaction is completed, the solvent is removed using a rotary evaporator or the like, and the resulting residue is purified by silica gel column chromatography to obtain the desired compound represented by formula (I).

[0053] Preparation of Pharmacologically Acceptable Salts of Compounds of Formula (I) The compounds of formula (I) can be converted into pharma- ceutically acceptable salts by reaction with a suitable acid or acid derivative. Suitable pharma-ceutically acceptable salts will be apparent to those skilled in the art. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, or organic acids such as oxalic acid, succinic acid, maleic acid, acetic acid, fumaric acid, citric acid, malic acid, tartaric acid, benzoic acid, p-toluic acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid or naphthalenesulfonic acid.

[0054] Preparation of stereoisomers of compounds of formula (I) Stereoisomers of compounds of formula (I) may be prepared by one or more of the conventional methods set out below. a. One or more of the reagents may be used in their optically active form. b. An optically pure catalyst or a metal catalyst together with a chiral ligand can be used in the reduction process. The metal catalyst can be rhodium, ruthenium, indium, etc. The chiral ligand is preferably a chiral phosphine.

[0055] c. Mixtures of stereoisomers can be optically resolved by conventional methods such as forming diastereomeric salts with chiral acids or chiral amines or chiral amino alcohols, or chiral amino acids. The resulting mixture of diastereomers can then be separated by methods such as fractional recrystallization, chromatography, etc., followed by an additional step of isolating the optically active products from the resolved material / salt. d. Mixtures of stereoisomers can be resolved by conventional methods such as microbial resolution, optical resolution of diastereomeric salts formed with chiral acids or chiral bases. Chiral acids that can be used can be tartaric acid, mandelic acid, lactic acid, camphorsulfonic acid, amino acids, etc. Chiral bases that can be used can be cinchona alkaloids, brucine, or basic amino acids such as lysine, arginine, etc.

[0056] In another embodiment, suitable pharma- ceutically acceptable salts include hydrochloride, hydrobromide, oxalate, fumarate, tartrate, maleate and succinate salts.

[0057] <Pharmaceutical Composition> In another aspect, the present invention relates to a pharmaceutical composition containing the compound represented by formula (I) of the present invention or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, in particular, the pharmaceutical composition of the present invention for treating or preventing pancreatic cancer. According to the present invention, it is possible to avoid serious side effects specific to anticancer drugs, while it is becoming clear that the more nutrient-starved cancer cells are, the higher their proliferation ability, metastasis ability, and even malignancy. This is thought to be closely related to cancer stem cells, and in fact, the expression of cancer stem cells is significantly increased in nutrient-starved states. If cancer stem cells are not effectively killed, it will eventually lead to cancer recurrence, which is extremely serious. The present invention is an approach that focuses particularly on cytotoxicity in the cancer microenvironment, i.e., in a nutrient-starved state, and is highly likely to be effective against these cancer stem cells, and proposes a groundbreaking drug that can effectively kill cancer cells through multiple mechanisms of action.

[0058] As used herein, "treatment" refers to a method or process that aims to (1) delay the onset of pancreatic cancer; (2) slow or stop the progression, progression or worsening of symptoms of pancreatic cancer; (3) bring about remission of symptoms of pancreatic cancer; or (4) cure pancreatic cancer. Treatment may be administered prior to the onset of the disease or condition as a preventative measure, or alternatively, treatment may be administered after initiation of the disease.

[0059] As used herein, "prevention" means preventing the onset of pancreatic cancer.

[0060] In the present invention, the pharmaceutical composition generally means a drug for treating or preventing a disease, or for testing or diagnosing a disease.

[0061] In the present invention, pancreatic cancer refers to cancer that occurs in cells of the pancreas, in which malignant (cancer) cells are found in pancreatic tissue, and is also called exocrine cancer.

[0062] In yet another aspect, the present invention relates to a compound of formula (I) for use in the treatment or prevention of pancreatic cancer.

[0063] In yet another aspect, the invention relates to the use of a compound of formula (I) in the manufacture of a medicament for treating or preventing pancreatic cancer.

[0064] In yet another aspect, the present invention relates to a combination of the compound of formula (I) with one or more other anticancer drugs. Examples of the combination of the compound of the present invention include gemcitabine, albumin-bound paclitaxel (nab-paclitaxel), TS-1, gemcitabine + albumin-bound paclitaxel, gemcitabine + TS-1, FOLFIRINOX (a multi-drug combination therapy of three types of anticancer drugs, 5-FU, irinotecan, and oxaliplatin, and levofolinate, which is a potentiator of 5-FU), modified FOLFIRINOX, and liposomal irinotecan + 5FU / LV.

[0065] In yet another aspect, the invention relates to pharmaceutical compositions of the compounds of formula (I). For therapeutic use of the compounds of formula (I), or their stereoisomers and pharma- ceutical acceptable salts, they are normally formulated into pharmaceutical compositions according to standard pharmaceutical practice.

[0066] The pharmaceutical compositions of the present invention can be formulated in a conventional manner using one or more pharma- ceutically acceptable excipients, such as diluents, disintegrants, binders, lubricants, glidants, polymers, coating agents, solvents, cosolvents, preservatives, wetting agents, thickeners, antifoaming agents, sweeteners, flavors, antioxidants, colorants, solubilizers, plasticizers, dispersing agents, and the like. The excipients are selected from among microcrystalline cellulose, mannitol, lactose, pregelatinized starch, sodium starch glycolate, corn starch or derivatives thereof, povidone, crospovidone, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, talc, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid or hydrogenated vegetable oils, gum arabic, magnesia, glucose, fats, waxes, natural or hardened oils, water, saline or alcohols, e.g. ethanol, propanol or sugar solutions such as glycerin, glucose solutions or mannitol solutions, or mixtures of a number of excipients.

[0067] The compounds of the present invention can be formulated into the form of tablets, coated tablets, capsules, powders, granules, liquids, semisolids, gels, aerosols, emulsions, elixirs, etc. Such pharmaceutical compositions and methods for their preparation are well known.

[0068] In yet another embodiment, the pharmaceutical composition of the present invention contains the compound of the present invention or a pharma- ceutically acceptable salt thereof in an amount of 1-90% by weight, 5-75% by weight, or 10-60% by weight. The amount of the compound of the present invention or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition may be in any range of about 1 mg to about 1000 mg, or about 5 mg to about 500 mg, or about 5 mg to about 250 mg, or a wider range than that. The specific dose of the compound of the present invention will vary depending on factors such as the age and weight of the patient, the nature and severity of the disease to be treated, and other factors.

[0069] In another aspect, the present invention relates to the use of a compound of the present invention, or a stereoisomer, tautomer, or a pharma- ceutical acceptable salt thereof, as an anti-cancer agent for selectively killing nutrient-starved tumor cells. In yet another aspect, the present invention relates to the use of the compound of the present invention, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, as an anticancer agent that targets the tumor microenvironment. EXAMPLES

[0070] The compounds of the present invention were prepared by the following experimental procedures using appropriate materials and conditions. The following examples are provided by way of illustration only and are not intended to limit the scope of the present invention.

[0071] Example 1 (trans-4'-methyl-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(4-methoxy-2,6-bis(methoxymethoxy)phenyl)methanone (Nico-1) [ka] Step 1: (E)-3-(4-methylphenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3a) Under Ar atmosphere, the corresponding benzaldehyde 2 (2.00 mmol) and barium hydroxide octahydrate (631 mg, 2.00 mmol) were added to a mixture of acetophenone 1 (1.25 mmol) in ethanol (7.5 mL) and water (1.5 mL) at room temperature, and the mixture was stirred at 60 °C for 22 h. Methanol was removed using a rotary evaporator, and the mixture was extracted with dichloromethane (1.5 mL × 3). The organic layers were combined and dried over anhydrous sodium sulfate, and the solvent was removed using a rotary evaporator. The residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 30 : 1 to 3 : 1) to obtain the desired chalcone 3a.

[0072] Yield: 94%; 1 H-NMR (400 MHz CDCl3) δ: 2.36 (3H, s), 3.38 (6H, s), 3.82 (3H, s), 5.11 (4H, s), 6.44 (2H, s), 6.93 (1H, d, J = 16.0 Hz), 7.18 (2H, d, J = 8.0 Hz), 7.32 (1H, d, J = 16.0 Hz), 7.41 (2H, d, J = 8.0 Hz).

[0073] Step 2: Title compound of Example 1 (Nico-1) Under Ar atmosphere, myrcene (3.17 mL, 75%, 14.0 mmol) was added to a solution of chalcone 3a (1.40 mmol) prepared in step 1 in benzene (15 mL) at room temperature, and the mixture was stirred at 160 °C in a sealed tube for 7 days. After removing benzene using a rotary evaporator, the resulting residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 50:1 to 3:1) to obtain the desired product and a mixture of its positional isomers (about 4:1). Next, p-toluenesulfonic acid monohydrate (133 mg, 0.07 mmol) was added to a mixed solution of the resulting mixture in methanol (2.5 mL) and dichloromethane (2.5 mL), and the mixture was stirred at 40 °C for 16 hours. After the reaction was completed, the solvent was removed using a rotary evaporator, and the resulting residue was purified by silica gel column chromatography (n-hexane:ethyl acetate = 50:1 to 10:1) to obtain the desired Nico-1.

[0074] Preparation Example Substantially following step 1 of Example 1, the following chalcone compounds were prepared: (E)-3-(4-methoxyphenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3b) Yield: 97%; 1 H-NMR (400 MHz CDCl3) δ: 3.88 (6H, s), 3.82 (3H, s), 3.83 (3H, s), 5.12 (4H, s), 6.44 (2H, s), 6.86 (1H, d, J = 16.2 Hz), 6.89 (2H, d, J = 9.0 Hz), 7.30 (1H, d, J = 16.2 Hz), 7.47 (d, J = 9.0 Hz).

[0075] (E)-3-(4-fluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3c) Yield: 94%; 1 H-NMR (400 MHz CDCl3) δ: 3.37 (6H, s), 3.81 (3H, s), 5.10 (4H, s), 6.42 (2H, s), 6.88 (1H, d, J = 12.8 Hz), 7.03-7.06 (2H, m), 7.30 (1H, d, J = 12.8 Hz), 7.47-7.50 (2H, m).

[0076] (E)-3-(4-chlorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3d) Yield: 84%; 1 H-NMR (400 MHz CDCl3) δ: 3.39 (6H, s), 3.82 (3H, s), 5.12 (4H, s), 6.43 (2H, s), 6.94 (1H, d, J = 16.0 Hz), 7.30 (1H, d, J = 16.0 Hz), 7.34 (2H, d, J = 8.6 Hz), 7.45 (2H, d, J = 8.6 Hz).

[0077] (E)-1-(3-methoxy-6-(methoxymethoxy)phenyl)-3-phenylprop-2-en-1-one (3e) Yield: 99%; 1 H-NMR (400 MHz CDCl3) δ: 3.50 (3H, s), 3.87 (3H, s), 5.26 (2H, s), 6.63 (1H, dd, J = 8.4, 2.0 Hz), 6.73 (1H, d, J = 2.0 Hz), 7.36-7.41 (4H, m), 7.50 (1H, d, J = 16.0 Hz), 7.58-7.60 (2H, m) 7.67 (1H, d, J = 16.0 Hz), 7.72 (1H, d, J = 8.4 Hz).

[0078] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-phenylprop-2-en-1-one (3f) Yield: 84%; 1 H-NMR (400 MHz CDCl3) δ: 3.39 (6H, s), 5.14 (4H, s), 6.86 (2H, d, J = 8.4 Hz), 6.98 (1H, d, J = 16.2 Hz), 7.30 (1H, t, J = 8.4 Hz), 7.31 (1H, d, J = 16.2 Hz), 7.36-7.40 (3H, m), 7.51-7.53 (2H, m).

[0079] (E)-1-(2-Methoxy-6-(methoxymethoxy)phenyl)-3-phenylprop-2-en-1-one (3g) Yield: 94%; 1 H-NMR (400 MHz CDCl3) δ: 3.38 (3H, s), 3.78 (3H, s), 3.14 (2H, s), 6.66 (1H, d, J = 8.0 Hz), 6.82 (1H, d, J = 8.0 Hz), 6.97 (1H, d, J = 16.2 Hz), 7.31 (1H, d, J = 16.2 Hz), 7.32 (1H, t, J = 8.0 Hz), 7.36-7.39 (3H, m), 7.50-7.53 (2H, m).

[0080] (E)-1-(6-Methoxy-3-(methoxymethoxy)phenyl)-3-phenylprop-2-en-1-one (3h) Compound 3h was prepared as described in G. Valdameri et al. J. Med. Chem., 2012, 55, 3193-3200.

[0081] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (3i) Yield: 95%; 1H-NMR (400 MHz CDCl3) δ: 3.38 (6H, s), 3.83 (3H, s), 5.13 (4H, s), 6.85 (2H, d, J = 8.4 Hz), 6.86 (1H, d, J = 16.4 Hz), 6.89 (2H, d, J = 8.4 Hz), 7.26 (1H, d, J = 16.4 Hz), 7.29 (1H, t, J = 8.4 Hz), 7.46 (2H, d, J = 8.4 Hz).

[0082] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(4-fluorophenyl)prop-2-en-1-one (3j) Yield: 84%; 1 H-NMR (400 MHz CDCl3) δ: 3.37 (6H, s), 5.14 (4H, s), 6.86 (2H, d, J = 9.2 Hz), 6.90 (1H, d, J = 16.0 Hz), 7.06 (1H, d, J = 9.2 Hz), 7.08 (1H, d, J = 8.4 Hz), 7.30 (2H, t, J = 8.4 Hz), 7.49-7.53 (2H, m).

[0083] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(4-chlorophenyl)prop-2-en-1-one (3k) Yield: 85%; 1 H-NMR (400 MHz CDCl3) δ: 3.38 (6H, s), 5.12 (4H, s), 6.86 (2H, d, J = 8.8 Hz), 6.94 (1H, d, J = 16.0 Hz), 7.27 (1H, d, J = 16.0 Hz), 7.30 (1H, t, J = 8.4 Hz), 7.35 (2H, d, J = 8.8 Hz), 7.45 (2H, d, J = 8.4 Hz).

[0084] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2-fluorophenyl)prop-2-en-1-one (3l) Yield: 90%; 1 H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 5.14 (4H, s), 6.86 (2H, d, J = 8.0 Hz), 7.05 (1H, d, J = 16.6 Hz), 7.07 (1H, td, J = 8.0, 0.8 Hz), 7.17 (1H, td, J = 8.0, 0.8 Hz), 7.30 (1H, t, J = 8.0 Hz), 7.33-7.39 (1H, m), 7.49 (1H, d, J = 16.6 Hz), 7.58 (1H, td, J = 8.0, 2.0 Hz).

[0085] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(3-fluorophenyl)prop-2-en-1-one (3m) Yield: 88%; 1 H-NMR (400 MHz CDCl3) δ: 3.39 (6H, s), 5.14 (4H, s), 6.86 (1H, d, J = 8.4 Hz), 6.95 (1H, d, J = 16.0 Hz), 7.06-7.10 (1H, m), 7.20-7.23 (1H, m), 7.27-7.35 (4H, m).

[0086] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(3,4-difluorophenyl)prop-2-en-1-one (3n) Yield: 55%; 1H-NMR (500 MHz CDCl3) δ: 3.41 (6H, s), 5.16 (4H, s), 6.87 (2H, d, J = 8.5 Hz), 6.89 (1H, d, J = 16.0 Hz), 7.13-7.25 (2H, m), 7.23 (1H, d, J = 16.0 Hz), 7.30 (1H, t, J = 8.5 Hz), 7.34 (1H, ddd, J = 16.0, 8.5, 2.0 Hz).

[0087] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,3-difluorophenyl)prop-2-en-1-one (3o) Yield: 100%; 1 H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 5.14 (4H, s), 6.87 (2H, d, J = 8.8 Hz), 7.06 (1H, d, J = 16.6 Hz), 7.06-7.13 (1H, m), 7.15-7.22 (1H, m), 7.27-7.35 (2H, m), 7.46 (1H, d, J = 16.6 Hz).

[0088] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,4-difluorophenyl)prop-2-en-1-one (3p) Yield: 83%; 1 H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 5.14 (4H, s), 6.84 (1H, ddd, J = 11.2, 8.4, 2.4 Hz), 6.86 (2H, d, J = 8.4 Hz), 6.88-6.94 (1H, m), 6.99 (1H, d, J = 16.4 Hz), 7.30 (1H, t, J = 8.4 Hz), 7.42 (1H, d, J = 16.4 Hz), 7.56 (1H, m).

[0089] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,5-difluorophenyl)prop-2-en-1-one (3q) Yield: 78%; 1 H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 5.14 (4H, s), 6.86 (2H, d, J = 8.4 Hz), 7.00 (1H, d, J = 16.4 Hz), 7.04 (2H, td, J = 6.2, 2.1 Hz), 7.23-7.28 (1H, m), 7.30 (1H, t, J = 8.4 Hz), 7.43 (1H, d, J = 16.4 Hz).

[0090] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,6-difluorophenyl)prop-2-en-1-one (3r) Yield: 92%; 1 H-NMR (400 MHz CDCl3) δ: 3.42 (6H, s), 5.15 (4H, s), 6.86 (2H, d, J = 8.4 Hz), 6.92 (2H, t, J = 8.4 Hz), 7.26 (1H, d, J = 16.4 Hz), 7.29 (2H, t, J = 8.4 Hz), 7.48 (1H, d, J = 16.4 Hz).

[0091] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(3,5-difluorophenyl)prop-2-en-1-one (3s) Yield: 93%; 1 H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 5.14 (4H, s), 6.83 (1H, tt, J = 6.4, 2.2 Hz), 6.86 (2H, d, J = 8.8 Hz), 6.93 (1H, d, J = 16.0 Hz), 7.00-7.05 (2H, m), 7.22 (1H, d, J = 16.0 Hz), 7.31 (1H, t, J = 8.8 Hz).

[0092] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2-chlorophenyl)prop-2-en-1-one (3t) Yield: 94%; 1 H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 5.15 (4H, s), 6.87 (2H, d, J = 8.0 Hz), 6.94 (1H, d, J = 16.4 Hz), 7.28-7.33 (3H, m), 7.37-7.40 (1H, m), 7.67-7.70 (1H, m), 7.74 (1H, d, J = 16.4 Hz).

[0093] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(3-chlorophenyl)prop-2-en-1-one (3u) Yield: 88%; 1 H-NMR (400 MHz CDCl3) δ: 3.39 (6H, s), 5.14 (4H, s), 6.86 (2H, d, J = 7.6 Hz), 6.96 (1H, d, J = 16.2 Hz), 7.25 (1H, d, J = 16.2 Hz), 7.28-7.36 (4H, m), 7.40 (1H, dt, J = 7.6, 1.6 Hz), 7.49 (1H, t, J = 1.6 Hz).

[0094] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,3-dichlorophenyl)prop-2-en-1-one (3v) Yield: 63%; 1H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 5.15 (4H, s), 6.87 (2H, d, J = 8.4 Hz), 6.91 (1H, d, J = 16.0 Hz), 7.24 (1H, t, J = 8.0 Hz), 7.31 (1H, t, J = 8.4 Hz), 7.48 (1H, dd, J = 8.4, 1.2 Hz), 7.58 (1H, dd, J = 8.0, 1.2 Hz), 7.73 (1H, d, J = 16.0 Hz).

[0095] (E)-1-(2,6-bis(methoxymethoxy)phenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one (3w) Yield: 82%; 1 H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 5.14 (4H, s), 6.87 (2H, J = 8.4 Hz), 6.91 (1H, d, J = 16.2 Hz), 7.26-7.29 (1H, m), 7.30 (1H, t, J = 8.4 Hz), 7.41 (1H, d, J = 1.2 Hz), 7.62 (1H, d, J = 8.4 Hz), 7.66 (1H, d, J = 16.2 Hz)

[0096] (E)-3-(2-fluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3x) Yield: 99%; 1 H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 3.83 (3H, s), 5.13 (4H, s), 6.44 (2H, s), 7.05 (1H, d, J = 16.4 Hz), 7.02-7.10 (1H, m), 7.16 (1H, t, J = 7.4 Hz), 7.32-7.38 (1H, m), 7.52 (1H, d, J = 16.4 Hz), 7.57 (1H, td, J = 7.4, 2.0 Hz).

[0097] (E)-3-(2,3-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3y) Yield: 96%; 1 H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 3.83 (3H, s), 5.13 (4H, s), 6.45 (2H, s), 7.07 (1H, d, J = 16.2 Hz), 7.06-7.21 (2H, m), 7.30-7.34 (1H, m), 7.49 (1H, d, J = 16.2 Hz).

[0098] (E)-3-(3-fluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3z) Yield: 91%; 1 H-NMR (400 MHz CDCl3) δ: 3.39 (6H, s), 3.82 (3H, s), 5.12 (4H, s), 6.44 (2H, s), 6.95 (1H, d, J = 16.4 Hz), 7.06 (1H, tdd, J = 8.4, 2.4, 1.2 Hz), 7.20-7.24 (1H, m), 7.27-7.37 (3H, m).

[0099] (E)-3-(2,4-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3aa) Yield: 91%; 1H-NMR (400 MHz CDCl3) δ: 3.40 (6H, s), 3.82 (3H, s), 5.13 (4H, s), 6.44 (2H, s), 6.84 (1H, ddd, J = 10.8, 8.4, 2.2 Hz), 6.91 (1H, td, J = 8.4, 2.2 Hz), 7.00 (1H, d, J = 16.0 Hz), 7.46 (1H, d, J = 16.0 Hz), 7.56 (1H, dd, J = 10.8, 8.4 Hz).

[0100] (E)-3-(2,5-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3ab) Yield: 70%; 1 H-NMR (400 MHz CDCl3) δ: 3.42 (6H, s), 3.83 (3H, s), 5.13 (4H, s), 6.45 (2H, s), 7.02 (1H, d, J = 16.0 Hz), 7.03-7.06 (2H, m), 7.34-7.27 (1H, m), 7.47 (1H, d, J = 16.0 Hz).

[0101] (E)-3-(2,6-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3ac) Yield: 83%; 1 H-NMR (400 MHz CDCl3) δ: 3.42 (6H, s), 3.82 (3H, s) 5.14 (4H, s), 6.44 (2H, s), 6.89-6.95 (2H, m), 7.25-7.32 (2H, m), 7.51 (1H, d, J = 16.8 Hz).

[0102] (E)-3-(3,4-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3ad) Yield: 74%; 1H-NMR (500 MHz CDCl3) δ: 3.39 (6H, s), 3.81 (3H, s), 5.11 (4H, s), 6.42 (2H, s), 6.87 (1H, d, J = 16.0 Hz), 7.15 (1H, dd, J = 17.5, 8.0 Hz), 7.22-7.25 (2H, m), 7.33 (1H, ddd, J = 10.0, 8.0, 1.8 Hz)

[0103] (E)-3-(3,5-difluorophenyl)-1-(4-methoxy-2,6-bis(methoxymethoxy)phenyl)prop-2-en-1-one (3ae) Yield: 78%; 1 H-NMR (400 MHz CDCl3) δ: 3.41 (6H, s), 3.83 (3H, s), 5.13 (4H, s), 6.44 (2H, s), 6.82 (1H, tt, J = 8.6, 2.3 Hz), 6.94 (1H, J = 16.2 Hz), 7.00-7.06 (2H, m), 7.27 (1H, d, J = 16.2 Hz).

[0104] Example 2-31 Compound Nico-2-31 represented by formula (I) was prepared by using compounds 3b-3ae prepared in Preparation Example and substantially following step 2 of Example 1. The correspondence between the chalcone compounds and the Nico compounds is as follows. [Table 1]

[0105] Example 2 (trans-4'-Methoxy-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(4-methoxy-2,6-bis(methoxymethoxy)phenyl)methanone (Nico-2) Yield: 38% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.60 (3H, s), 1.69 (3H, s), 1.99-2.22 (7H, m), 2.51-2.55 (1H, m), 3.25 (1H, td, J = 11.0, 5.2 Hz), 3.73 (6H, s), 4.38 (1H, td, J = 11.0, 5.2 Hz), 5.09-5.12 (1H, m), 5.50 (1H, br), 5.85 (2H, s), 6.74 (2H, d, J = 9.0 Hz), 7.13 (2H, d, J = 9.0 Hz).

[0106] Example 3 (trans-4'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(4-methoxy-2,6-bis(methoxymethoxy)phenyl)methanone (Nico-3) Yield: 53% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.00-2.26 (7H, m), 2.52-2.57 (1H, m), 3.23 (1H, td, J = 11.0, 5.2 Hz), 3.75 (3H, s), 4.34 (1H, td, J = 10.8, 5.2 Hz), 5.09-5.11 (1H, m), 5.51 (1H, br), 5.85 (2H, s), 6.87 (2H, t, J = 8.6 Hz), 7.15-7.18 (2H, m).

[0107] Example 4 (trans-4'-chloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(4-methoxy-2,6-bis(methoxymethoxy)phenyl)methanone (Nico-4) Yield: 24% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.60 (3H, s), 1.69 (3H, s), 2.00-2.25 (7H, m), 2.52-2.57 (1H, m), 3.28 (1H, td, J = 11.0, 5.2 Hz), 3.75 (3H, s), 4.38 (1H, td, J = 11.0, 5.2 Hz), 5.09-5.12 (1H, m), 5.50 (1H, br), 5.86 (2H, s), 7.12-7.15 (4H, m).

[0108] Example 5 (2-Hydroxy-4-methoxyphenyl)(trans-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanone (Nico-5) Yield: 63% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.62 (3H, s), 1.70 (3H, s), 2.03-2.40 (8H, m), 3.30 (1H, td, J = 11.2, 5.9 Hz), 3.79 (3H, s), 3.83-3.89 (1H, m), 5.10-5.14 (1H, m), 5.51 (1H, br), 6.31 (1H, d, J = 2.0 Hz), 6.40 (1H, dd, J = 9.2, 2.4 Hz), 7.09 (1H, dd, J = 9.2, 4.4 Hz), 7.17-7.19 (4H, m), 7.73 (1H, d, J = 9.2 Hz), 12.90 (1H, s).

[0109] Example 6 (trans-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-6) Yield: 56% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.67 (3H, s), 2.01-2.29 (7H, m), 2.56-2.62 (1H, m), 3.29 (1H, td, J = 10.8, 5.2 Hz), 4.45 (1H, td, J = 10.8, 5.2 Hz), 5.10-5.13 (1H, m), 5.52 (1H, br), 6.30 (2H, d, J = 8.4 Hz), 7.09-7.22 (6H, m), 9.12 (1H, br).

[0110] Example 7 (2-Hydroxy-6-methoxyphenyl)(trans-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanone (Nico-7) Yield: 55% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.62 (3H, s), 1.70 (3H, s), 2.01-2.53 (7H, m), 3.27 (1H, td, J = 10.8, 5.2 Hz), 3.94 (3H, s), 4.28 (1H, td, J = 10.8, 5.2 Hz), 5.10-5.14 (1H, m), 5.52 (1H, br), 6.36 (1H, d, J = 8.4 Hz), 6.42 (1H, J = 8.4 Hz), 7.07-7.11 (1H, m), 7.14-7.17 (4H, m), 7.22-7.25 (1H, m), 12.45 (1H, s).

[0111] Example 8 (trans-2,6-Dimethoxyphenyl)(trans-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanone (Nico-8) Yield: 58% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.60 (3H, s), 1.69 (3H, s), 1.97-2.45 (8H, m), 3.21 (1H, td, J = 10.0, 6.0 Hz), 3.50 (1H, td, J = 10.0, 6.0 Hz), 3.62 (6H, s), 5.08-5.12 (1H, m), 5.48 (1H, br), 6.42 (2H, d, J = 8.4 Hz), 7.08-7.11 (1H, m), 7.13-7.21 (5H, m).

[0112] Example 9 (trans-4'-Methoxy-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-9) Yield: 43% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 2.02-2.27 (7H, m), 2.54-2.58 (1H, m), 3.25 (1H, td, J = 11.4, 5.6 Hz), 3.72 (3H, s), 4.40 (1H, td, J = 11.4, 5.6 Hz), 5.10-5.12 (1H, m), 5.51 (1H, br), 6.30 (2H, d, J = 8.8 Hz), 6.73 (2H, d, J = 8.8 Hz), 7.12 (2H, d, J = 8.8 Hz), 7.15 (1H, t, J = 8.8 Hz), 9.08 (1H, br).

[0113] Example 10 (trans-4'-Fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-10) Yield: 38% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 1.99-2.27 (7H, m), 2.54-2.60 (1H, m), 3.28 (1H, td, J = 11.0, 5.2 Hz), 4.40 (1H, td, J = 11.0, 5.2 Hz), 5.09-5.11 (1H, m), 6.31 (2H, J = 8.0 Hz), 6.83-6.92 (2H, m), 7.14-7.18 (3H, m), 9.06 (1H, br).

[0114] Example 11 (trans-4'-chloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-11) Yield: 39% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.00-2.25 (7H, m), 2.55-2.60 (1H, m), 3.28 (1H, td, J = 11.2, 5.2 Hz), 4.41 (1H, td, J = 10.0, 5.2 Hz), 5.09-5.12 (1H, m), 5.51 (1H, br), 6.31 (2H, d, J = 8.4 Hz), 7.14-7.19 (5H, m), 9.25 (1H, br).

[0115] Example 12 (trans-2'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-12) Yield: 64% (after 2 steps); 1H-NMR (500 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 1.97-2.33 (7H, m), 2.62-2.65 (1H, m), 3.52 (1H, td, J = 11.0, 5.2 Hz), 4.56 (1H, td, J = 11.0, 5.2 Hz), 5.11 (1H, tt, J = 5.0, 1.3 Hz), 5.51 (1H, d, J = 5.0 Hz), 6.32 (2H, d, J = 8.0 Hz), 6.90-6.97 (1H, m), 6.95 (1H, t, J = 8.0 Hz), 7.05-7.10 (1H, m), 7.14-7.19 (2H, m), 7.44 (1H, br).

[0116] Example 13 (trans-3'-フルオロ-5-(4-メチルペンタ-3-エン-1-イル)-1,2,3,6-テトラヒNico-13 Yield: 49% (after 2 projects); 1 H-NMR (500 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 2.00-2.29 (7H, m), 2.58 (1H, dt, J = 17.0, 5.0 Hz), 3.31 (1H, td, J = 10.5, 5.0 Hz), 4.44 (1H, td, J = 10.5, 5.0 Hz), 5.11 (1H, tt, J = 7.0, 1.5 Hz), 5.51 (1H, d, J = 4.5 Hz), 6.32 (2H, d, J = 7.0 Hz), 6.78 (1H, tdd, J = 8.0, 2.0, 1.5 Hz), 6.93 (1H, dt, J = 10.0, 2.0 Hz), 6.99 (1H, d, J = 8.0 Hz), 7.12-7.18 (2H, m), 9.26 (1H, br).

[0117] Example 14 (trans-3',4'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-14) Yield: 45% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 2.00-2.26 (7H, m), 2.58 (1H, dt, J = 16.5, 5.0 Hz), 3.31 (1H, td, J = 8.5, 5.0 Hz), 5.11 (1H, tt, J = 7.0, 1.0 Hz), 5.51 (1H, d, J = 4.0 Hz), 6.33 (2H, d, J = 8.5 Hz), 7.01-7.15 (3H, m), 7.28 (1H, t, J = 8.5 Hz), 9.46 (1H, br).

[0118] Example 15 (trans-2',3'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-15) Yield: 20% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.02-2.33 (7H, m), 2.64 (1H, d, J = 15.6 Hz), 3.65 (1H, td, J = 11.2, 5.2 Hz), 4.55 (1H, td, J = 11.2, 5.2 Hz), 5.09-5.12 (1H, m), 6.34 (2H, d, J = 8.4 Hz), 6.83-6.94 (3H, m), 7.17 (1H, t, J = 8.4 Hz), 9.38 (1H, br).

[0119] Example 16 (trans-2',4'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-16) Yield: 52% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.01-2.29 (7H, m), 2.58-2.64 (1H, m), 3.57 (1H, td, J = 11.2, 5.2 Hz), 4.50 (1H, td, J = 11.2, 5.2 Hz), 5.09-5.12 (1H, m), 5.50 (1H, br), 6.32 (2H, d, J = 8.0 Hz), 6.65-6.71 (2H, m), 7.09-7.13 (1H, m), 7.17 (1H, t, J = 8.0 Hz), 9.21 (1H, br).

[0120] Example 17 (trans-2',5'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-17) Yield: 63% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.01-2.32 (7H, m), 2.59-2.65 (1H, m), 3.61 (1H, td, J = 10.8, 5.2 Hz), 4.48 (1H, td, J = 10.8, 5.2 Hz), 5.08-5.12 (1H, m), 5.51 (1H, br), 6.33 (2H, d, J = 8.4 Hz), 6.72-6.78 (1H, m), 6.85-6.93 (2H, m), 7.18 (1H, t, J = 8.4 Hz), 9.23 (1H, br).

[0121] Example 18 (trans-2',6'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-18) Yield: 54% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.62 (3H, s), 1.70 (3H, s), 2.02-2.21(6H, m), 2.41-2.66 (2H, m), 3.74 (1H, td, J = 11.7, 4.9 Hz), 4.68-4.73 (1H, m), 5.09-5.13 (1H, m), 5.51 (1H, br), 6.31 (2H, d, J = 8.8 Hz), 6.73 (2H, t, J = 8.8 Hz), 7.00-7.08 (1H, m), 7.16 (1H, t, J = 8.8 Hz), 9.17 (1H, br).

[0122] Example 19 (trans-3',5'-difluoro5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-19) Yield: 35% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 2.01-2.23 (7H, m), 2.69 (1H, d, J = 13.6 Hz), 3.31 (1H, td, J = 8.4, 4.4 Hz), 4.23 (1H, br), 5.11 (1H, d, J = 6.0 Hz), 5.51 (1H, s), 6.35 (2H, d, J = 6.0 Hz), 6.54 (1H, t, J = 6.0 Hz), 6.76 (2H, d, J = 6.0 Hz), 7.18 (1H, t, J = 6.0 Hz), 9.48 (1H, br).

[0123] Example 20 (trans-2'-chloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-20) Yield: 63% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 1.97-2.43 (7H, m), 2.65 (1H, dt, J = 16.4, 5.0 Hz), 3.87 (1H, td, J = 11.0, 5.0 Hz), 4.57 (1H, td, J =11.0, 5.0 Hz), 5.09-5.11 (1H, m), 5.51 (1H, br), 5.51 (1H, s), 6.35 (2H, d, J = 6.5 Hz), 6.54 (1H, t, J = 8.0 Hz), 6.34 (2H, d, J = 8.0 Hz), 7.00-7.10 (2H, m), 7.16-7.20 (2H, m), 7.31-7.33 (1H, m).

[0124] Example 21 (trans-3'-chloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-21) Yield: 41% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.70 (3H, s), 2.00-2.28 (7H, m), 2.55-2.60 (1H, m), 3.28 (1H, td, J = 10.8, 5.2 Hz), 4.44 (1H, td, J = 10.8, 5.2 Hz), 5.09-5.13 (1H, m), 5.51 (1H, d, J = 3.6 Hz), 6.32 (2H, d, J = 8.0 Hz), 7.05-7.11 (3H, m), 7.16 (1H, t, J = 8.0 Hz), 7.22 (1H, s), 9.33 (1H, br).

[0125] Example 22 (trans-2',3'-dichloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-22) Yield: 41% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.01-2.24 (6H, m), 2.38-2.67 (2H, m), 3.92 (1H, td, J = 11.2, 5.0 Hz), 4.56 (1H, td, J = 11.2, 5.0 Hz), 5.10 (1H, tt, J = 5.6, 1.6 Hz), 5.50 (1H, br), 6.36 (2H, d, J = 8.4 Hz), 6.96-7.02 (1H, m), 7.06-7.10 (1H, m), 7.20 (1H, t, J = 8.4 Hz), 7.23 (1H, dd, J = 8.4, 1.6 Hz), 9.34 (1H, br).

[0126] Example 23 (trans-2',4'-dichloro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-23) Yield: 63% (after 2 steps); 1H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 1.93-2.24 (6H, m), 2.33-2.38 (1H, m), 2.62-2.67 (1H, m), 3.82 (1H, td, J = 11.2, 5.0 Hz), 4.52 (1H, td, J = 11.2, 5.0 Hz), 5.09-5.12 (1H, m), 5.51(1H, br), 6.35 (2H, d, J = 8.0 Hz), 7.05 (1H, dd, J = 8.0, 2.4 Hz), 7.11 (1H, d, J = 8.0 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.34 (1H, d, J = 2.4 Hz).

[0127] Example 24 (trans-4'-Fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-24) Yield: 47% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.00-2.32 (7H, m), 2.57-2.62 (1H, m), 3.52 (1H, td, J = 10.6, 5.6 Hz), 3.75 (3H, s), 4.48 (1H, td, J = 10.6, 5.6 Hz), 5.11 (1H, t, J = 7.0 Hz), 5.50 (1H, d, J = 4.4 Hz), 5.86 (2H, s), 6.92-6.97 (2H, m), 7.05-7.10 (1H, m), 7.17 (1H, td, J = 8.0, 2.0 Hz).

[0128] Example 25 (trans-2',3'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-25) Yield: 51% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.00-2.32 (7H, m), 2.61 (1H, dt, J = 15.6, 5.0 Hz), 3.65 (1H, td, J = 11.0, 5.0 Hz), 3.75 (3H, s), 4.48 (1H, td, J = 11.0, 5.0 Hz), 5.10 (1H, tt, J = 7.0, 1.4 Hz), 5.51 (1H, d, J = 4.0 Hz), 5.87 (2H, s), 6.85-6.95 (3H, m).

[0129] Example 26 (trans-3'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-26) Yield: 26% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.60 (3H, s), 1.69 (3H, s), 2.00-2.28 (7H, m), 2.56 (1H, dt, J = 16.8, 5.2 Hz), 3.32 (1H, td, J = 10.0, 5.2 Hz), 3.74 (3H, s), 4.42 (1H, td, J = 10.0, 5.2 Hz), 5.11 (1H, tt, J = 6.8, 2.0 Hz), 5.51 (1H, d, J = 3.6 Hz), 5.87 (2H, s), 6.79 (1H, td, J = 8.0, 2.0 Hz), 6.93 (1H, dt, J = 10.0, 2.0 Hz), 7.00 (1H, d, J = 8.0 Hz), 7.15 (1H, dd, J = 14.0, 8.0 Hz).

[0130] Example 27 (trans-2',4'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-27) Yield: 50% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.60 (3H, s), 1.68 (3H, s), 2.00-2.38 (7H, m), 2.57-2.62 (1H, m), 3.58 (1H, td, J = 11.2, 5.0 Hz), 3.74 (3H, s), 4.66 (1H, td, J = 11.2, 5.0 Hz), 5.10 (1H, td, J = 6.4, 1.6 Hz), 5.50 (1H, d, J = 3.2 Hz), 5.88 (2H, s), 6.64-6.72 (2H, m), 7.13 (1H, dd, J = 14.8, 8.4 Hz).

[0131] Example 28 (trans-2',5'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-28) Yield: 20% (after 2 steps); 1 H-NMR (400 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.00-2.31 (7H, s), 2.60 (1H, d, J = 16.4 Hz), 3.62 (1H, td, J = 11.0, 5.2 Hz), 3.75 (3H, s), 4.45 (1H, td, J = 11.0, 5.2 Hz), 5.10 (1H, t, J = 6.8 Hz), 5.50 (1H, br), 5.88 (2H, s), 6.72-6.78 (1H, m), 6.86-6.93 (2H, m).

[0132] Example 29 (trans-2',6'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-29) Yield: 43% (after 2 steps); 1 H-NMR (500 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 2.43 (1H, t, J = 14.5 Hz), 2.61 (1H, dt, J = 12.0, 4.5 Hz), 3.73 (3H, s), 3.72-3.77 (1H, m), 4.67 (1H, tt, J = 12.0, 4.5 Hz), 5.11 (1H, t, J = 6.5 Hz), 5.51 (1H, d, J = 4.5 Hz), 5.86 (2H, s), 6.74 (2H, t, J = 8.0 Hz), 7.04 (1H, ddd, J = 15.0, 8.0, 6.5 Hz).

[0133] Example 30 (trans-3',4'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-30) Yield: 41% (after 2 steps); 1 H-NMR (500 MHz CDCl3) δ: 1.61 (3H, s), 1.69 (3H, s), 1.99-2.25 (7H, s), 2.55 (1H, dt, J = 17.0, 5.0 Hz), 3.27 (1H, td, J = 11.0, 5.0 Hz), 3.75 (3H, s), 4.35 (1H, td, J = 11.0, 5.0 Hz), 5.10 (1H, t, J = 7.0 Hz), 5.50 (1H, d, J = 4.0 Hz), 5.87 (2H, s), 6.91-6.99 (2H, m), 7.00-7.05 (1H, m).

[0134] Example 31 (trans-3',5'-fluoro-5-(4-methylpent-3-en-1-yl)-1,2,3,6-tetrahydro-[1,1'-biphenyl]-2-yl)(2,6-dihydroxyphenyl)methanone (Nico-31) Yield: 59% (after 2 steps); 1 H-NMR (500 MHz CDCl3) δ: 1.60 (3H, s), 1.69 (3H, s), 1.98-2.26 (7H, s), 2.57 (1H, dt, J = 17.0, 5.0 Hz), 3.31 (1H, td, J = 10.8, 5.0 Hz), 3.75 (3H, s), 4.39 (1H, td, J = 10.8, 5.0 Hz), 5.10 (1H, t, J = 6.5 Hz), 5.50 (1H, d, J = 3.5 Hz), 5.89 (2H, s), 6.54 (1H, tt, J = 8.0, 2.0 Hz), 6.76 (2H, dd, J = 8.0, 2.0 Hz).

[0135] Test Example 1 Morphological changes in cancer cells induced by Nicolaidecin C (NICO-C) We investigated the effect of NICO-C on the morphological changes of pancreatic cancer cells (PANC-1 and MIA PaCa-2) that undergo cell death under nutrient-deprived conditions using acridine orange (AO) / ethidium bromide (EB) double staining fluorescence. In detail, PANC-1 (RBRC-RCB2095) and MIA PaCa-2 (RBRC-RCB2094) cells purchased from the Riken BRC Cell Bank were cultured in 12-well plates in nutrient starvation medium (NDM: 265 mg / L CaCl2(2H2O), 0.1 mg / L Fe(NO3)(9H2O), 400 mg / L KCl, 200 mg / L MgSO4(7H2O), 6,400 mg / L NaCl, 700 mg / L NaHCO3, 125 mg / L NaH2PO4, 15 mg / L phenol red, 25 mmol / L HEPES buffer (pH 7.4), MEM vitamin solution (Life Technologies, Inc., Rockville, MD); final pH was adjusted to 10%. Cells were treated with nicolaidecin C at concentrations of 1.25 μM, 2.5 μM and 5 μM, as well as untreated controls, in 100 mM NaHCO3 (adjusted to 7.4 with NaHCO3) and incubated for 24 h. Cells were then stained with the DNA intercalating agents acridine orange (AO) and ethidium bromide (EB) and photographed in fluorescence (red and green) and phase contrast modes. The results obtained are shown in Figure 1. AO is a dye that penetrates the cell membrane and emits bright green fluorescence in live cells (white area in Figure 1). On the other hand, EB is only capable of penetrating the membrane of dead and dying cells and stains red when intercalated into double-stranded DNA (main staining area is indicated by the white arrow in Figure 1). During the process of cell death, the integrity of the cell membrane is loosened and both EB and AO reagents penetrate into the cells and emit orange or red fluorescence (dying, dead cells). Untreated control PANC-1 cells only emitted bright green fluorescence, and cell morphology and chromatin organization were intact, whereas treatment with NICO-C induced a concentration-dependent increase in red fluorescent EB-stained cells, revealing a clear change in cell morphology.When PANC-1 cells were incubated with 5 μM NICO-C, they emitted exclusively red EB fluorescence, and showed rounded cell morphology, cell membrane bullets, cell membrane rupture, and leakage of cell contents into the culture medium. In Figure 1, "phase contrast" represents the result of converting the phase difference of light rays into contrast, and "overlay" represents the overlay of green fluorescence + red fluorescence + black and white images of each row. Phase contrast allows visualization of cells and cell components that are difficult to see with a normal optical microscope. Overlay provides detailed information on the cell's life or death state (morphology, whether EBs are concentrated in the cell due to destruction of the cell membrane, etc.). Live cells emit bright green fluorescence due to only AO penetrating into the cell, and dead cells emit pink fluorescence due to EBs. In overlay, if a cell emits pink fluorescence in the nucleus and the same cell emits green fluorescence, it is information that indicates the cell death process is occurring.

[0136] Test Example 2 Effect of nicolaidecin C (NICO-C) on colony formation by PANC-1 cells PANC-1 cells (5000 cells / well) were seeded in 12-well plate dishes in DMEM (1 mL / well) and incubated for 24 h to allow the cells to attach. The medium was then changed to DMEM containing 0 μM (control) or 10, 20, or 40 μM NICO-C in DMEM. PANC-1 tumor cells were exposed for 24 h, with three replicates for each group. The cells were then washed twice with PBS and the medium was replaced with fresh DMEM (2 mL) without the test compound. The cells were then cultured for 12 days. On the final day, the cells were washed with PBS, then fixed with 4% formaldehyde and stained with crystal violet for 10 min. The results are shown in Figure 2A. Figure 2B is a graph showing the average area occupied by PANC-1 cell colonies (three replicates).

[0137] Test Example 3 Effect of Nicolaidecin C (NICO-C) on autophagy signaling pathway Proteins were separated by gel electrophoresis on a polyacrylamide gel containing 0.1% sodium dodecyl sulfate and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with Block Ace (DS Pharma Medical, Suita, Japan), washed with Dulbecco's phosphate-buffered saline containing 0.1% polyoxyethylene (20) sorbitan monolaurate (Wako Pure Chemical Industries, Ltd.), and then incubated overnight with primary antibodies diluted in Can Get Signal (Toyobo, Osaka, Japan). After washing, the membrane was incubated for 45 min at room temperature with horseradish peroxidase-conjugated anti-rabbit or anti-goat immunoglobulin as the secondary antibody. Bands were detected with enhanced chemiluminescence solution (PerkinElmer, Inc.). The results obtained are shown in Figures 3, 4, and 5.

[0138] Figure 3 shows the effect of NICO-C on key proteins involved in the activation of Akt / mTOR and autophagy pathways. NICO-C selectively inhibited p-Akt and p-mTOR in starvation conditions in a concentration-dependent manner. Meanwhile, no obvious changes in Akt / mTOR protein were observed in DMEM. These data strongly suggest that inhibition of the Akt / mTOR signaling pathway contributes significantly to the selective cytotoxicity of NICO-C against the tested pancreatic cancer cells in NDM. Furthermore, as shown in Figure 3, NICO-C suppressed the expression of autophagy markers LC3-I and LC3-II in a concentration-dependent manner. These results suggest that NICO-C is a potent inhibitor of autophagy.

[0139] Figure 4 shows the results of suppressing the expression of LC3, a key marker of autophagy, by co-treating NICO-C with 3-MA (3-methyladenine), an inhibitor of early stage autophagy, or CQ (chloroquine), an inhibitor of late stage autophagy. When PANC-1 was treated with 20 μM NICO-C, the expression of both LC3-I and LC3-II was significantly suppressed. In addition, when NICO-C and CQ were used together, the expression of LC3-II was suppressed compared to CQ alone. In addition, in the Western blot of LC3-II in Figure 4, the band was thick in the second from the left (treated only with CQ, a late stage inhibitor), and was faint in the third (treated only with 3-MA, an early stage inhibitor), and similarly in the fourth (treated only with NICO-C). These data suggest that NICO-C inhibits autophagy at the early stage.

[0140] Figure 5 shows the effect of coadministration of NICO-C on insulin-like growth factor-I (IGF)-induced Akt phosphorylation in comparison with the Akt inhibitor compound [(2R)-2-methoxy-3-octadecoxypropyl][2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl]carbonate. NICO-C (20 μM) completely suppressed Akt phosphorylation under starvation conditions. Furthermore, NICO-C was found to suppress IGF-I-stimulated Akt activation. The inhibitory effect of NICO-C on Akt phosphorylation is comparable to that of the Akt inhibitor compound.

[0141] Test Example 4 Effect of Nicolaidecin C (NICO-C) on the growth of MIA PaCa-2 tumors in nude mice Five-week-old male BALB / c nude mice (CAnN, Cg-Fixbk <nu>Mice (5W♂ / CrlCrlJ) were acclimated in the animal house for 1 week. MIA PaCa-2 tumor cells (10,000,000 cells / 200 mL PBS) were injected subcutaneously into the left and right flanks of all mice. Six days after tumor cell inoculation, mice (n=8 / group) were randomly divided into three groups: (i) control, (ii) low-dose NICO-C (50 μg / day), and (iii) high-dose NICO-C (250 μg / day). Mice were injected intraperitoneally with NICO-C (treatment group) or PBS (control group) five times per week. All mice had free access to solid food and water. Body weight and tumor size were measured twice a week using the following formula: (i) control, (ii) low-dose NICO-C (50 μg / day), and (iii) high-dose NICO-C (250 μg / day). The results are shown in Figure 6B.

[0142] Estimated tumor volume (measured twice weekly) = (π × length × width 2 ) / 6

[0143] Figure 6A shows the body weight of the animals measured twice a week, and there was no significant difference in the body weight between the treatment group and the NICO-C-treated group during the experimental period. As can be seen from the tumor growth curves of the tumor sizes measured twice a week shown in Figure 6B, the tumor volume steadily increased in the control group, while the increase in tumor volume in the NICO-C-treated group was dose-dependently suppressed.

[0144] Drug treatment was continued for 5 weeks, and on the 34th day, the mice were sacrificed by CO2 narcosis, the tumors were harvested, and their wet weights were measured. The results are shown in Figure 6C. The average wet weight of the tumors in the control group was significantly higher than that in the NICO-C-treated group (Figure 6C). The results in Figures 6B and C indicate that NICO-C and its derivatives exert antitumor activity in vivo. All results of statistical analysis were expressed as mean ± SD. Statistical comparisons were performed using ANOVA followed by Student's t-test. Results were considered significant when P<0.05.

[0145] Test Example 5 Selective cytotoxic activity assay against PANC-1 cells PANC-1 (RBRC-RCB2095, Tsukuba, Japan) human pancreatic cancer cell line was purchased from Riken BRC Cell Bank. The human pancreatic cancer cells were maintained in standard Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified incubator with 5% CO2 and 95% air at 37 °C. Briefly, human pancreatic cancer cells were seeded in 96-well plates (15000 / well) and cultured in DMEM for 24 h at 37 °C in a 5% CO2 and 95% air incubator. After washing the cells twice with phosphate-buffered saline (PBS), the medium was replaced with nutrient-rich medium (DMEM) and nutrient-starved medium (NDM: 265 mg / L CaCl2(2H2O), 0.1 mg / L Fe(NO3)(9H2O), 400 mg / L KCl, 200 mg / L MgSO4(7H2O), 6,400 mg / L NaCl, 700 mg / L NaHCO3, 125 mg / L NaH2PO4, 15 mg / L phenol red, 25 mmol / L HEPES buffer (pH 7.4), MEM vitamin solution (Life Technologies, Inc., Rockville, VA, USA) containing controls and blanks for each test. The test compound samples (NICO-C, NICO-1 to NICO-31) were serially diluted in both DMEM and NDM. Here, the term "control" refers to culture wells containing only cancer cells, i.e. reflecting cytotoxicity to cancer cells in the absence of test compound administration, and the term "blank" refers to culture wells without cancer cells, i.e. reflecting values ​​from culture medium alone. After 24 h of incubation with each test compound in DMEM and NDM, the medium in each well was replaced with DMEM containing 100 μL 10% WST-8 cell counting kit solution. After a further 3 h of incubation, the absorbance at 450 nm was measured with an EnSpire multimode plate reader (PerkinElmer, Inc., Waltham, USA). Cell viability was calculated from the average value from triplicate wells using the following formula:

[0146] Cell viability (%) = "Abs(test sample) - Abs(blank) / Abs(control) - Abs(blank)" x 100% Here, a "blank" refers to a culture well that does not contain cancer cells, and a "control" refers to a culture well that contains only cancer cells.

[0147] Graphs obtained by plotting the concentration of the test compound in the sample versus the cell viability (%) are shown in Figures 7A-7D. These figures show that all of the test compounds NICO-1 to NICO-31 selectively kill tumor cells in a nutrient-starved state versus a fed state, as does NICO-C, which has been shown to cause morphological changes in cancer cells, inhibit colony formation of cancer cells, inhibit the autophagy signaling pathway, and inhibit tumor growth.

[0148] The example compounds and NICO-C in the present invention are summarized below together with their structures and PC50 values. Compounds that show selective cytotoxicity against nutrient-starved cancer cells are classified as antistringent agents, and their activity is expressed by PC50 value. Here, "PC50 value" means the concentration at which 50% of cancer cells are selectively killed in nutrient-starved (NDM) medium and show no obvious toxicity in nutrient-rich normal medium (DMEM).

[0149] [ka]

[0150] [Table 2] < / nu>

Claims

1. Formula (I): [Formula 1] [In the formula, R 1 ~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, any of which (except hydrogen, hydroxy and halogen) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -N(CH 3 ) 2 , halogen, hydroxy, -NH 2 and -CN. However, R 1 is methoxy, R 2 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is hydrogen, R 3 and R 4 is hydroxy. or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

2. Formula (I): [chemical 2] [In the formula, R 1 ~R 5 are each independently hydrogen, hydroxy, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, any of which (except hydrogen and hydroxy) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -N(CH 3 ) 2 , halogen, hydroxy, -NH 2 and -CN; R 6 ~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -(C 6-10 )aryl or -(C 5-10 ) heteroaryl, any of which (except hydrogen, hydroxy and halogen) is —(C 1-6 ) alkyl, -O-(C 1-6 ) alkyl, -S-(C 1-6 ) alkyl, -(C 3-6 ) cycloalkyl, halo(C 1-6 ) alkyl, -N(CH 3 ) 2 , halogen, hydroxy, -NH 2 and -CN.

2. The compound according to claim 1, wherein:

3. In formula (I), R 1 ~R 5are each independently hydrogen, hydroxy or -O-(C 1-6 3. The compound according to claim 1 or 2, wherein R is 1 or 2 is 1 or 2 is 2 or 3. The compound according to claim 1 or 2, wherein R is 1 or 2 is 2 or 3.

4. In formula (I), R 1 is hydrogen or -O-(C 1-6 4. The compound of claim 1, wherein R is 1 or 2; or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

5. In formula (I), R 2 5. The compound of claim 1, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein is hydrogen.

6. In formula (I), R 3 is hydroxy or -O-(C 1-6 6. The compound of claim 1, wherein R is 0 or 1; R is 1 or 2; and R is 2 or 3.

7. The compound of claim 1, wherein R is 1 or 2;

7. In formula (I), R 4 is hydrogen, hydroxy or -O-(C 1-6 7. The compound of claim 1, wherein R is 0 or 1; R is 1 or 2; and R is 2 or 3. The compound of claim 1, wherein R is 1 or 2;

8. In formula (I), R 5 8. The compound of claim 1, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein: is hydrogen.

9. In formula (I), R 6 ~R 10 are each independently hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl or -O-(C 1-6 9. The compound of claim 1, wherein R is 0 or 1; R is 1 or 2; and R is 2 or 3. The compound of claim 1, wherein R is 1 or 2;

10. In formula (I), R 6 10. The compound of claim 9, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein is hydrogen or halogen.

11. In formula (I), R 7 11. The compound according to claim 9 or 10, wherein is hydrogen or halogen, or a stereoisomer, tautomer, or a pharma- ceutically acceptable salt thereof.

12. In formula (I), R 8 is hydrogen, hydroxy, halogen, -(C 1-6 ) alkyl or -O-(C 1-6 12. The compound of claim 9, wherein R is 1 or 2; or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

13. In formula (I), R 6 , R 7 and R 8 12. The compound of any one of claims 9 to 11, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein one or more of is halogen.

14. In formula (I), R 9 14. The compound of any one of claims 9 to 13, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein is hydrogen or halogen.

15. In formula (I), R 10 15. The compound of any one of claims 9 to 14, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, wherein is hydrogen or halogen.

16. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 15, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.

17. 17. The pharmaceutical composition of claim 16, which selectively kills nutrient-starved tumor cells.

18. 18. The pharmaceutical composition of claim 16 or 17, which targets the tumor microenvironment.

19. 19. The pharmaceutical composition according to any one of claims 16 to 18, for treating or preventing pancreatic cancer.

20. 16. A pharmaceutical composition based on a compound of formula (I) as defined in any one of claims 1 to 15, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, in combination with at least one other anti-cancer agent.

21. A pharmaceutical composition based on the combination described in claim 20, wherein the other anticancer drug is selected from the group consisting of gemcitabine, albumin-bound paclitaxel, TS-1, gemcitabine and albumin-bound paclitaxel, gemcitabine and TS-1, forfirinox therapy, modified forfirinox therapy, and liposomal irinotecan and 5FU / LV.

22. 20. Use of a compound according to any one of claims 1 to 15, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, as an anti-cancer agent for selectively killing nutrient-starved tumor cells.

23. 20. Use of a compound according to any one of claims 1 to 15, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, as an anti-cancer agent that targets the tumor microenvironment.